EP1599577A4 - Modele animal cliniquement pertinent du cancer du sein humain et implication du vegf dans la reponse desmoplastique, la resistance au tamoxifene et la metastase - Google Patents

Modele animal cliniquement pertinent du cancer du sein humain et implication du vegf dans la reponse desmoplastique, la resistance au tamoxifene et la metastase

Info

Publication number
EP1599577A4
EP1599577A4 EP04715174A EP04715174A EP1599577A4 EP 1599577 A4 EP1599577 A4 EP 1599577A4 EP 04715174 A EP04715174 A EP 04715174A EP 04715174 A EP04715174 A EP 04715174A EP 1599577 A4 EP1599577 A4 EP 1599577A4
Authority
EP
European Patent Office
Prior art keywords
vegf
involvement
metastasis
breast cancer
animal model
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP04715174A
Other languages
German (de)
English (en)
Other versions
EP1599577A2 (fr
Inventor
Zhican Qu
Frances Kern
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Southern Research Institute
Original Assignee
UAB Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UAB Research Foundation filed Critical UAB Research Foundation
Publication of EP1599577A2 publication Critical patent/EP1599577A2/fr
Publication of EP1599577A4 publication Critical patent/EP1599577A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/50—Fibroblast growth factors [FGF]

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP04715174A 2003-02-26 2004-02-26 Modele animal cliniquement pertinent du cancer du sein humain et implication du vegf dans la reponse desmoplastique, la resistance au tamoxifene et la metastase Ceased EP1599577A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44998003P 2003-02-26 2003-02-26
US449980P 2003-02-26
PCT/US2004/006052 WO2004076648A2 (fr) 2003-02-26 2004-02-26 Modele animal cliniquement pertinent du cancer du sein humain et implication du vegf dans la reponse desmoplastique, la resistance au tamoxifene et la metastase

Publications (2)

Publication Number Publication Date
EP1599577A2 EP1599577A2 (fr) 2005-11-30
EP1599577A4 true EP1599577A4 (fr) 2007-06-06

Family

ID=32927597

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04715174A Ceased EP1599577A4 (fr) 2003-02-26 2004-02-26 Modele animal cliniquement pertinent du cancer du sein humain et implication du vegf dans la reponse desmoplastique, la resistance au tamoxifene et la metastase

Country Status (6)

Country Link
EP (1) EP1599577A4 (fr)
JP (1) JP2006519018A (fr)
CN (1) CN1780554A (fr)
AU (1) AU2004214892B8 (fr)
CA (1) CA2517082A1 (fr)
WO (1) WO2004076648A2 (fr)

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
BORGSTROEM P ET AL: "IMPORTANCE OF VEGF FOR BREAST CANCER ANGIOGENESIS IN VIVO: IMPLICATIONS FROM INTRAVITAL MICROSCOPY OF COMBINATION TREATMENTS WITH AN ANTI-VEGF NEUTRALIZING MONOCLONAL ANTIBODY AND DOXORUBICIN", ANTICANCER RESEARCH, HELENIC ANTICANCER INSTITUTE, ATHENS,, GR, vol. 19, no. 5B, 1999, pages 4203 - 4214, XP009032786, ISSN: 0250-7005 *
BULLOCKS J ET AL: "Overexpression of vascular endothelial cell growth factor (VEGF) in MCF-7 breast carcinoma cells facilitates growth in tamoxifen-treated nude mice and tumor cell dissemination", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 38, no. 0, 1997, & EIGHTY-EIGHTH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; SAN DIEGO, CALIFORNIA, USA; APRIL 12-16, 1997, pages 525, XP001245623, ISSN: 0197-016X *
DATABASE BIOTECHNOLOGY DERWENT PUBLICATIONS, LONDON, GB; *
FOEKENS JOHN A ET AL: "High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER REREARCH, US, vol. 61, no. 14, 15 July 2001 (2001-07-15), pages 5407 - 5414, XP002425575, ISSN: 0008-5472 *
H. AKBULUT, ET AL: "The effects of chemotherapeutic drugs on VEGF secretion of solid tumors", JOURNAL OF CLINICAL ONCOLOGY, vol. 28, no. 15SUPPL, E13123, 20 May 2010 (2010-05-20), XP009138587 *
KLEINMAN H K ET AL: "BASEMENT MEMBRANE COMPLEXES WITH BIOLOGICAL ACTIVITY", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, vol. 25, no. 2, 1 January 1986 (1986-01-01), pages 312 - 318, XP009117119, ISSN: 0006-2960, DOI: 10.1021/BI00350A005 *
ORIMO AKIRA ET AL: "Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion", CELL, vol. 121, no. 3, May 2005 (2005-05-01), pages 335 - 348, XP009138583, ISSN: 0092-8674, DOI: 10.1016/j.cell.2005.02.034 *
QU Z ET AL: "USE OF AN IMPROVED DOXYCYCLINE-REGULATED TRANSACTIVATOR TO STUDY THE MECHANISM OF TAMOXIFEN RESISTANCE MEDIATED BY INCREASED ANGIOGENESIS IN BREAST CANCER XENOGRAFTS", PROCEEDINGS OF THE 93RD ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. SAN FRANCISCO, CA, APRIL 6 - 10, 2002, PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, PHILADELPHIA, PA : AACR, US, vol. VOL. 43, March 2002 (2002-03-01), pages 1056, XP008045743 *
QU ZHICAN ET AL: "Doxycycline-regulated expression of VEGF-A165 in MCF-7 breast cancer cells demonstrates its ability to enhance estrogen-stimulated tumor growth, tamoxifen resistance and macrometastatic potential.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 44, July 2003 (2003-07-01), & 94TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; WASHINGTON, DC, USA; JULY 11-14, 2003, pages 992, XP001249097, ISSN: 0197-016X *
QU ZHICAN ET AL: "Vascular endothelial growth factor reduces tamoxifen efficacy and promotes metastatic colonization and desmoplasia in breast tumors", CANCER RESEARCH, vol. 68, no. 15, August 2008 (2008-08-01), pages 6232 - 6240, XP009138584, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-07-5654 *
SHU X ET AL: "Sphingosine kinase mediates vascular endothelial growth factor-induced activation of Ras and mitogen-activated protein kinases", MOLECULAR AND CELLULAR BIOLOGY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, US, vol. 22, no. 22, 1 November 2002 (2002-11-01), pages 7758 - 7768, XP002999707, ISSN: 0270-7306, DOI: 10.1128/MCB.22.22.7758-7768.2002 *
TAUB ET AL: "Epidermal growth factor or transforming growth factor alpha is required for kidney tubulogenesis in matrigel cultures in serum-free medium.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 87, no. 10, 1 May 1990 (1990-05-01), pages 4002 - 4006, XP055002548, ISSN: 0027-8424 *
Y. LIANG: "Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones", ENDOCRINE RELATED CANCER, vol. 13, no. 3, 1 September 2006 (2006-09-01), pages 905 - 919, XP055002547, ISSN: 1351-0088, DOI: 10.1677/erc.1.01221 *
ZHANG LURONG ET AL: "Overexpression of fibroblast growth factor 1 in MCF-7 breast cancer cells facilitates tumor cell dissemination but does not support the development of macrometastases in the lungs or lymph nodes", CANCER RESEARCH, vol. 59, no. 19, 1 October 1999 (1999-10-01), pages 5023 - 5029, XP000982519, ISSN: 0008-5472 *
ZHI-MING SHAO ET AL: "Human breast carcinoma desmoplasia is PDGF initiated", ONCOGENE, vol. 19, no. 38, 1 September 2000 (2000-09-01), pages 4337 - 4345, XP055035070, ISSN: 0950-9232, DOI: 10.1038/sj.onc.1203785 *

Also Published As

Publication number Publication date
WO2004076648A2 (fr) 2004-09-10
AU2004214892B2 (en) 2009-01-22
WO2004076648A9 (fr) 2005-01-20
WO2004076648A3 (fr) 2005-06-02
AU2004214892A1 (en) 2004-09-10
AU2004214892B8 (en) 2009-05-28
CN1780554A (zh) 2006-05-31
JP2006519018A (ja) 2006-08-24
EP1599577A2 (fr) 2005-11-30
CA2517082A1 (fr) 2004-09-10

Similar Documents

Publication Publication Date Title
FR2877389B1 (fr) Ensemble a garniture d'etancheite gonflable dans un puits de forage
EP1747043A4 (fr) Matrice d'interface bio-electro-physiologique implantable
EP2064334A4 (fr) Marqueurs d'aldéhyde et utilisations de ceux-ci dans le cadre d'une modification de protéines en un site spécifique
IS8054A (is) Kannabinóíð viðtaka bindlar og notkun þeirra
IS8137A (is) Kannabinóíð viðtaka bindlar og notkun þeirra
EP1774025A4 (fr) Identification de marqueurs dans le cancer du poumon et dans le cancer du sein
DE602005020738D1 (de) Ultraschallsonde
DK1691837T3 (da) IP-10-antistoffer og anvendelse heraf
DE602005011644D1 (de) Ultraschallsonde und Ultraschalldiagnosegerät
EP1718120A4 (fr) Element d'affichage
DE60312119D1 (de) Blutentnahmeset mit Entlüftungsmechanismus
EP1693005A4 (fr) Echographe et echographie
DE602005018137D1 (de) Konfigurierbares System für das Alarmieren von Pflegern
DE602004010764D1 (de) Ultraschallschneider
EP1615944A4 (fr) Antiandrogenes presentant une activite agoniste marginale, et methodes d'utilisation
EP1813194A4 (fr) Sonde ultrasonore
EP1633317A4 (fr) Ligands des recepteurs des chimiokines synthetiques et leurs methodes d'utilisation
EP1802764A4 (fr) Marqueurs biologiques destines au cancer du sein
DE602004017945D1 (de) Strömungsgerät mit mehreren Einheiten
EP1425575A4 (fr) Nouveau marqueur du cancer et ses utilisations dans le diagnostic du cancer
DE602005005282D1 (de) Neigungssensor und sein Befestigungsverfahren
EP1591117A4 (fr) Inhibiteur de proteine de resistance de cancer du sein (bcrp)
EP1599577A4 (fr) Modele animal cliniquement pertinent du cancer du sein humain et implication du vegf dans la reponse desmoplastique, la resistance au tamoxifene et la metastase
DE602005015505D1 (de) Diagnostisches Ultraschallgerät
DE602004022697D1 (de) Ultraschall-doppler-blutflussmessgerät

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050916

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/63 20060101ALI20060608BHEP

Ipc: C12N 5/00 20060101ALI20060608BHEP

Ipc: A61K 48/00 20060101ALI20060608BHEP

Ipc: A01K 67/00 20060101ALI20060608BHEP

Ipc: A01K 67/033 20060101AFI20060608BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20070507

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SOUTHERN RESEARCH INSTITUTE

17Q First examination report despatched

Effective date: 20090512

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20130207